SANA BIOTECHNOLOGY INCSANA
ASignal's systematic analysis rates SANA as Bearish.
Reflects the latest available analysis · analyzed Sep 19, 2026
The case on SANA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Oversold RSI at 23.9 suggests potential reversal
- Cash position exceeds total debt ($160.49M vs $80.94M)
- Debt-to-equity ratio of 0.52x is within moderate range
- Negative MACD histogram and MACD below signal line indicate bearish momentum
- Negative return on equity (-152.87%) and negative return on assets (-29.16%)
- Operating cash flow is significantly negative at $-132.24M
- No Reddit mentions, indicating low retail investor interest
- Forward P/E of -5.58x and negative EV/EBITDA suggest unprofitability
See the full verdict on SANA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SANA
Most investors never get a second opinion, let alone several. ASignal runs SANA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.